$103.97
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Overview
52-week range
$61
$122
70% of range
Avg surprise (last 3)
-9.2%
Avg reaction (last 2)
+5.5%
100% positive
Latest IV / EM
67%
EM ±15.3% · $105 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.83 | $-0.86 | +3.5% | -2.5% | +7.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.82 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.75 | $-0.66 | -13.6% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.81 | $-0.69 | -17.4% | — | +3.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.73 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.55 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.35 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.76 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.82 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.82 | -$0.75 | -9.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $7M | — | $5M | $6M | $4M | — | $4M | $3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-52M | — | $-53M | $-45M | $-47M | — | $-44M | $-40M |
| Net income | $-56M | — | $-53M | $-47M | $-49M | — | $-44M | $-32M |
| EPS (diluted) | $-0.83 | — | $-0.82 | $-0.75 | $-0.81 | — | $-0.73 | $-0.55 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $62M | $54M | $52M | $136M | $106M | $89M | $48M | $162M |
| Inventory | $29M | $26M | $22M | $19M | $19M | $19M | $14M | $12M |
| Total current assets | $430M | $467M | $495M | $361M | $369M | $374M | $340M | $357M |
| Total assets | $442M | $480M | $507M | $373M | $387M | $392M | $364M | $382M |
| Long-term debt | $98M | $101M | $103M | $106M | $108M | $108M | — | — |
| Total liabilities | $205M | $210M | $211M | $239M | $224M | $228M | $211M | $202M |
| Total equity | $123M | $139M | $149M | $-12M | $19M | $22M | $11M | $39M |